Best pharmaceutical stocks to buy in 2022
Invezz is an independent platform with the goal of helping users achieve financial freedom. In order to fund our work, we partner with advertisers who compensate us for users that Invezz refers to their services. While our reviews and assessments of each product on the site are independent and unbiased, brands may pay to appear higher up our table rankings or place ads in specific areas of the site. The order in which products and services appear on Invezz does not represent an endorsement from us, and please be aware that there may be other platforms available to you than the products and services that appear on our website. Read more about how we make money >
This page gives you our top five pharma companies to invest in right now. Our experts have analysed the markets to choose the most potential stocks and a solid track record of success. Keep reading to find out which ones we’ve chosen, along with the reasons why.
What are the top pharmaceutical stocks to buy?
The table below ranks the best pharma companies in order of their future growth potential, as chosen by our team of experts. You can quickly find their up-to-date stock price through the table below, or scroll down to find out more information about each company.
|#||Stock symbol||Company name||Trade now|
|3||JNJ||Johnson & Johnson|
|4||TEVA||Teva Pharmaceuticals Limited|
1. Pfizer Inc. (NYSE:PFE)
Pfizer is an American pharmaceutical company that’s been around since 1849. It’s been most famous in recent years for its work on the coronavirus vaccine, but it has been successful developing treatments for things like breast cancer, arthritis, and stroke as well.
The COVID-19 vaccine, based on revolutionary ‘messenger RNA’ (mRNA) technology, is the key driver of Pfizer’s recent good performance and what earns it top spot on this list. The market for the vaccine is obviously huge, and the share price has reacted positively each time the company has been able to announce good news.
Looking ahead, Pfizer is starting to translate the vaccine development into long term revenues, having already signed contracts for more than $20bn worth of sales in the months and years ahead. It’s also been able to add hundreds of millions more to its R&D budget to develop more treatments using mRNA, so the future looks bright indeed.
2. Moderna Inc. (NASDAQ: MRNA)
Moderna is a much younger company, having only been founded in 2010. It uses mRNA technology exclusively to develop treatments, which was completely unproven until 2020. But Moderna’s own coronavirus vaccine was a proof-of-concept and catapulted the company into becoming a serious pharmaceutical player.
Until then, Moderna’s price was based almost entirely on speculation. Even so, the potential of mRNA treatments, which alter human cells directly and open up all sorts of opportunities to fight disease, was enough to turn Moderna into the biggest biotech IPO in history.
Moderna has always acted as much like a tech startup as a pharmaceutical company, prioritising growth over profits. That already led to its value increasing five times over in 2020, and its single-minded attitude means a higher likelihood of new treatments sending the price even higher in future.
3. Johnson & Johnson (NYSE: JNJ)
Johnson & Johnson is a giant, it’s one of the largest companies in the world and has been at the forefront of American healthcare for decades. It takes in around $90bn in revenue every year and sells everyday consumer healthcare products as well as developing its own treatments.
Pharmaceuticals bring in more than half J&J’s revenue, so researching new drugs and vaccines is crucial to the business. It has earned its place on this list by developing new cancer treatments in particular in recent years, which has meant the stock price has been trending up for a long time.
While J&J might not give you explosive growth, it’s a company you can rely on. It has increased its dividend for 58 straight years in a row, and seen off every different type of economic environment. There’s no reason to expect that to change any time soon.
4. Teva Pharmaceutical Industries Ltd (TLV:TEVA)
Teva is an Israeli-based pharma company that specialises in developing ‘generic’ drugs. That means it produces copycat versions of drugs created by other companies to sell at a lower cost once the patent for the original runs out.
Generic drugs are big business, and Teva is the largest manufacturer of them in the world. Despite that, it’s gone through a tough few years that have sent its stock price falling by more than 50% since 2015.
It’s made this list as one of the cheapest pharma companies out there. It still rakes in more than $15bn in revenue every year but its share price is significantly lower than the competition. As a company trading well below its value, it could represent a bounce back candidate for anyone who wants to take the plunge right now.
5. Novartis AG (SWX:NOVN)
Novartis is based in Switzerland and one of the biggest pharmaceutical companies in the world, ranking up there with Johnson & Johnson and Pfizer in terms of market cap. It develops a range of its own treatments for cancer, epilepsy, and kidney disease, among many others.
It makes this list, like J&J, thanks to its strong track record of reliable returns. It has increased its dividend for 24 years in a row and has been steadily increasing its share price since a major company restructure in 2015.
As with both J&J and Pfizer, Novartis is an ideal investment for anyone looking for slow and steady, reliable growth. It might even be undervalued compared to those two giants, so it represents an attractive opportunity to value investors looking for stocks trading below their market value.
Where to buy the best pharmaceutical shares
To get any shares, you need a reliable stockbroker. These are some of the best stock platforms around, all of which offer top-of-the-range features and are ideal for if you can want to get started in the markets quickly.
What is a pharmaceutical stock?
Any company that develops, manufactures, or distributes products like drugs and vaccines. One of the defining features of pharmaceutical companies is how much they spend on research and development to discover new treatments. They also tend to be ‘defensive’ investments, because they can perform well in difficult economic environments.
Are pharmaceutical shares a good investment?
Yes, if you’re looking for steady and reliable returns rather than big growth opportunities. Occasionally biotech companies like Moderna grow rapidly, but in general the industry is more slow and steady than ‘to the moon’.
The big advantage of pharma stocks is that they can perform well even when the economy is struggling. Owning shares that aren’t affected too much by recessions can be a great way of balancing your portfolio, reducing your risk, and generating reliable returns.
As with any investment, it’s important to follow what’s going on in the news that might affect the pharmaceutical industry. New treatments and drug trials, for example, can directly impact the stock price of all companies in the sector. You can use our news section below to stay up to date.
Latest pharmaceuticals news
Gina Sanchez makes a bull case for Eli Lilly & Co
Rite Aid stock crashed 30% on Thursday: this is why
Biogen stock pumps 48% amid upgrade. What to watch out for
Should you buy Cassava Sciences as the stock continue to soar
Biogen stock shot up 40% on Wednesday: find out why
Moderna stock remains a great pick for long-term investors: Analyst
Invezz is a place where people can find reliable, unbiased information about finance, trading, and investing – but we do not offer financial advice and users should always carry out their own research. The assets covered on this website, including stocks, cryptocurrencies, and commodities can be highly volatile and new investors often lose money. Success in the financial markets is not guaranteed, and users should never invest more than they can afford to lose. You should consider your own personal circumstances and take the time to explore all your options before making any investment. Read our risk disclaimer >